Trials / Terminated
TerminatedNCT00048659
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM598 |
Timeline
- Completion
- 2004-06-01
- First posted
- 2002-11-06
- Last updated
- 2012-06-07
Locations
53 sites across 10 countries: United States, Australia, Belgium, France, Germany, Ireland, Netherlands, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00048659. Inclusion in this directory is not an endorsement.